TY - JOUR
T1 - Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy
T2 - A Combined Population-based Analysis
AU - Palumbo, Carlotta
AU - Pecoraro, Angela
AU - Knipper, Sophie
AU - Rosiello, Giuseppe
AU - Tian, Zhe
AU - Shariat, Shahrokh F.
AU - Simeone, Claudio
AU - Briganti, Alberto
AU - Saad, Fred
AU - Berruti, Alfredo
AU - Antonelli, Alessandro
AU - Karakiewicz, Pierre I.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Aim: This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan–Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated. Results: Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively. Conclusion: Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible.
AB - Aim: This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan–Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated. Results: Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively. Conclusion: Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible.
KW - Complication
KW - Metastasectomy
KW - Metastasis
KW - Renal cell carcinoma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85070721903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070721903&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13604
DO - 10.21873/anticanres.13604
M3 - Article
C2 - 31366530
AN - SCOPUS:85070721903
VL - 39
SP - 4357
EP - 4361
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 8
ER -